Search Results - "GRUEL, Y."

Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants by Touzé, E., Gruel, Y., Gouin‐Thibault, I., De Maistre, E., Susen, S., Sie, P., Derex, L.

“…Background and purpose Whereas intravenous thrombolysis (IVT) is allowed for acute ischaemic stroke in patients on vitamin K antagonists with international…”
Get full text

Laboratory testing for heparin‐induced thrombocytopenia: a conceptual framework and implications for diagnosis by WARKENTIN, T. E., GREINACHER, A., GRUEL, Y., ASTER, R. H., CHONG, B. H.

Get full text

Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory by Hardy, M, Lecompte, T, Douxfils, J, Lessire, S, Dogné, J M, Chatelain, B, Testa, S, Gouin-Thibault, I, Gruel, Y, Medcalf, R L, Ten Cate, H, Lippi, G, Mullier, F

“…Coronavirus disease 2019 (COVID-19) is associated with extreme inflammatory response, disordered hemostasis and high thrombotic risk. A high incidence of…”
Get full text

Prospective evaluation of the ‘4Ts’ score and particle gel immunoassay specific to heparin/PF4 for the diagnosis of heparin‐induced thrombocytopenia by POUPLARD, C., GUERET, P., FOUASSIER, M., TERNISIEN, C., TROSSAERT, M., RÉGINA, S., GRUEL, Y.

“…Background: Heparin‐induced thrombocytopenia (HIT) is a severe disease that is often difficult to diagnose. A clinical scoring system, the ‘4Ts’ score, has…”
Get full text

5B9, a monoclonal antiplatelet factor 4/heparin IgG with a human Fc fragment that mimics heparin‐induced thrombocytopenia antibodies by Kizlik‐Masson, C., Vayne, C., McKenzie, S. E., Poupon, A., Zhou, Y., Champier, G., Pouplard, C., Gruel, Y., Rollin, J.

“…Essentials No humanized monoclonal antibody was available to study heparin‐induced thrombocytopenia (HIT). We developed the first anti‐platelet factor 4…”
Get full text

Post‐operative platelet count profile: the most reliable tool for identifying patients with true heparin‐induced thrombocypenia after cardiac surgery by GRUEL, Y., POUPLARD, C.

Get full text

Specificities of neonatal hemostasis and implications in pathologic situations by Gruel, Y

“…The haemostasis of healthy newborn differs from those of normal adult but remains well balanced without bleeding or thrombosis. However, this equilibrium is…”
Get full text

The Taipan snake venom time can be used to detect lupus anticoagulant in patients treated by rivaroxaban by Pouplard, C., Vayne, C., Berthomet, C., Guery, E. A., Delahousse, B., Gruel, Y.

Get full text

Management of antiplatelet therapy for non elective invasive procedures of bleeding complications: proposals from the French working group on perioperative haemostasis (GIHP), in collaboration with the French Society of Anaesthesia and Intensive Care Medicine (SFAR) by Godier, A, Garrigue, D, Lasne, D, Fontana, P, Bonhomme, F, Collet, JP, de Maistre, E, Ickx, B, Gruel, Y, Mazighi, M, Nguyen, P, Vincentelli, A, Albaladejo, P, Lecompte, T

“…The French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Haemostasis and Thrombosis (GFHT) in collaboration with the French…”
Get full text

Post-authorization safety study of Clottafact®, a triply secured fibrinogen concentrate in congenital afibrinogenemia. A prospective observational study by Négrier, C., Rothschild, C., Borg, J.-Y., Lambert, T., Claeyssens, S., Sanhes, L., Stieltjes, N., Bertrand, A., André, M.-H., Sié, P., Gruel, Y., Tellier, Z.

“…Background and Objectives A new fibrinogen concentrate Clottafact® was developed according to European guidelines on plasma‐derived products. A…”
Get full text

Immunogenicity, efficacy and safety of Nuwiq® (human‐cl rhFVIII) in previously untreated patients with severe haemophilia A—Interim results from the NuProtect Study by Liesner, R. J., Abashidze, M., Aleinikova, O., Altisent, C., Belletrutti, M. J., Borel‐Derlon, A., Carcao, M., Chambost, H., Chan, A. K. C., Dubey, L., Ducore, J., Fouzia, N. A., Gattens, M., Gruel, Y., Guillet, B., Kavardakova, N., El Khorassani, M., Klukowska, A., Lambert, T., Lohade, S., Sigaud, M., Turea, V., Wu, J. K. M., Vdovin, V., Pavlova, A., Jansen, M., Belyanskaya, L., Walter, O., Knaub, S., Neufeld, E. J.

“…Introduction Nuwiq® (Human‐cl rhFVIII) is a fourth generation recombinant FVIII, produced in a human cell line, without chemical modification or protein…”
Get full text

Impact of polymorphisms affecting the ACP1 gene on levels of antibodies against platelet factor 4–heparin complexes by Rollin, J., Pouplard, C., Leroux, D., May, M.‐A., Gruel, Y.

Get full text

Neonatal arterial ischemic stroke: Which thrombotic biological risk factors to investigate and which practical consequences? by Perez, T, Valentin, J B, Saliba, E, Gruel, Y

“…All biological risk factors that have been previously identified to increase the risk of thrombosis in adults, have also been studied in neonates with arterial…”
Get full text

Tumor expression of alternatively spliced tissue factor is a prognostic marker in non‐small cell lung cancer by ROLLIN, J., REGINA, S., GRUEL, Y.

Get full text

JAK2 V617F is specifically associated with idiopathic splanchnic vein thrombosis by REGINA, S., HERAULT, O., D'ALTEROCHE, L., BINET, C., GRUEL, Y.

Get full text

Postauthorization safety study of Clottafact®, a triply secured fibrinogen concentrate in acquired fibrinogen deficiency: a prospective observational study by Négrier, C., Ducloy‐Bouthors, A.‐S., Piriou, V., De Maistre, E., Stieltjes, N., Borel‐Derlon, A., Colson, P., Picard, J., Lambert, T., Claeyssens, S., Boileau, S., Bertrand, A., André, M.‐H., Fourrier, F., Ozier, Y., Sié, P., Gruel, Y., Tellier, Z.

“…Background and Objectives A postauthorization safety study was performed between 2009 and 2012 to describe the use of Clottafact® in acquired fibrinogen…”
Get full text

Anti‐A2 and anti‐A1 domain antibodies are potential predictors of immune tolerance induction outcome in children with hemophilia A by Lapalud, P., Rothschild, C., Mathieu‐Dupas, E., Balicchi, J., Gruel, Y., Laune, D., Molina, F., Schved, J. F., Granier, C., Lavigne‐Lissalde, G.

“…Summary Background Hemophilia A (HA) is a congenital bleeding disorder resulting from factor VIII deficiency. The most serious complication of HA management is…”
Get full text

Expression and methylation status of tissue factor pathway inhibitor-2 gene in non-small-cell lung cancer by ROLLIN, J, IOCHMANN, S, BLECHET, C, HUBE, F, REGINA, S, GUYETANT, S, LEMARIE, E, REVERDIAU, P, GRUEL, Y

“…Tissue factor pathway inhibitor-2 (TFPI-2) is a Kunitz-type serine proteinase inhibitor that inhibits plasmin-dependent activation of several…”
Get full text

The IgG autoimmune response in postpartum acquired hemophilia A targets mainly the A1a1 domain of FVIII by LAPALUD, P., ALI, T., CAYZAC, C., MATHIEU‐DUPAS, E., LEVESQUE, H., PFEIFFER, C., BALICCHI, J., GRUEL, Y., BORG, J. Y., SCHVED, J. F., GRANIER, C., LAVIGNE‐LISSALDE, G.

“…Background:  Acquired hemophilia A (AHA) is a severe life‐threatening autoimmune disease due to the development of autoantibodies that neutralize the…”
Get full text

Binding of heparin‐dependent antibodies to PF4 modified by enoxaparin oligosaccharides: evaluation by surface plasmon resonance and serotonin release assay by LEROUX, D., CANÉPA, S., VISKOV, C., MOURIER, P., HERMAN, F., ROLLIN, J., GRUEL, Y., POUPLARD, C.

“…Background: The minimal structural requirements of low‐molecular‐weight heparins that determine the risk of developing heparin‐induced thrombocytopenia (HIT)…”
Get full text